ADDISON, Texas, June 2, 2016 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR), a specialty pharmaceutical company focused on the development and commercialization of a portfolio of wound care and wound management products utilizing its innovative Nanoflex® Aggregate technology, and mucoadhesive drug delivery film products to provide improved clinical outcomes through controlled delivery of active molecules utilizing its OraDisc™ transmucosal delivery system, is pleased to provide an update on the Company's corporate and business operational activities.
Expanded Distribution Network
ULURU Inc. has entered into a cooperation agreement with Saraya Co. Ltd. ("Saraya") for the registration of Altrazeal® and further cooperation in Japan. Saraya is a leading company engaged in the development, manufacture, distribution, and sales of a variety of human health, sanitation, hygiene products, and related equipment not only in Japan but all over the world.
"Saraya is a great partner for the registration of our product Altrazeal® in Japan," commented Helmut Kerschbaumer, Uluru's interim Chief Executive Officer. "Saraya has an excellent market reputation and a large sales force focused on the medical community." Product registration will commence immediately and the Company is hopeful that the registration process will be completed by year-end 2017 although regulatory approval can be unpredictable. Mr. Kerschbaumer continued, "The commencement of registration of Altrazeal® in Japan now brings the total number of markets in the process of registration to 38, which includes certain countries in Asia, the Middle East, and Latin America. This, coincidentally, is also the number of markets (38) in which Altrazeal® is already registered, including the United States and countries throughout the European Union."
Regarding the cooperation agreement, Saraya commented, "It is our great pleasure to have a business relationship with ULURU Inc. and their innovative wound care product Altrazeal®. We look forward to the future development through collaboration between us."
About Saraya Co. Ltd.
Since its establishment in 1952, Saraya (based in Osaka, Japan) has focused on three related themes - "Hygiene", "Environment" and "Health" - and aimed at the realization of richer and more productive world. Today Saraya, with more than 1,700 employees and about 50 domestic sales offices, is a market leader in the healthcare and sanitation industry. In recent years, through fundamental research and other innovation initiatives, Saraya has extended its scope of activities and developed a range of skin care products and disinfectants, among others. For further information about Saraya Co., Ltd., please visit our website at http://worldwide.saraya.com/.
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development and commercialization of a portfolio of wound care and wound management products utilizing its innovative Nanoflex® Aggregate technology, and mucoadhesive drug delivery film products to provide patients and consumers improved clinical outcomes through controlled delivery of active molecules utilizing its innovative OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.
ULURU Inc. (OTCQB: ULUR) trades on the OTCQB Venture stage marketplace for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the risk that we will not be able to successfully manage our distribution relationships, that we will be successful in registering and receiving regulatory authorizations in new territories, and the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and other reports filed by us with the Securities and Exchange Commission.
Contact: Company
Helmut Kerschbaumer
Interim President & CEO
Terrance K. Wallberg
Vice President & CFO
(214) 905-5145
SOURCE ULURU Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article